Anixa Biosciences (NASDAQ: ANIX) CEO buys 5,000 shares, now holds 652,000

Rhea-AI Filing Summary

Amit Kumar, Chief Executive Officer and director of Anixa Biosciences Inc, purchased 5,000 shares of common stock on July 27, 2026 in a transaction reported as a purchase in open market or private transaction at $3.44 per share, bringing his directly held stake to 652,000 shares.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider KUMAR AMIT

Role Chief Executive Officer

Bought 5,000 shs ($17K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$3.44	$17K

Holdings After Transaction: Common Stock — 652,000 shares (Direct)

Key Figures

Shares purchased: 5,000 shares Purchase price: $3.44 per share Shares owned after transaction: 652,000 shares +1 more

4 metrics

Shares purchased 5,000 shares Common stock bought by CEO Amit Kumar on July 27, 2026

Purchase price $3.44 per share Price for the 5,000 ANIX common shares purchased

Shares owned after transaction 652,000 shares Directly held ANIX common stock by Amit Kumar following the trade

Transaction date July 27, 2026 Date of the reported Form 4 purchase transaction

Key Terms

Form 4, Rule 10b5-1, open market or private transaction, direct or indirect ownership

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Rule 10b5-1 regulatory

"aff_10b5_one is the filing's document-level Rule 10b5-1 checkbox"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"transaction_code_description: Purchase in open market or private transaction"

direct or indirect ownership financial

"direct_or_indirect uses D/I for Direct/Indirect ownership type"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 10:20 AM Accepted by SEC EDGAR 07/28/2026 - 10:20 AM Learn about SEC filing dates

FAQ

What insider transaction did ANIX report for CEO Amit Kumar?

Amit Kumar, CEO of Anixa Biosciences (ANIX), purchased 5,000 shares of common stock on July 27, 2026 at $3.44 per share. This open-market or private transaction increased his directly held position to 652,000 shares.

How many Anixa Biosciences (ANIX) shares does Amit Kumar own after this Form 4?

After the reported purchase, Amit Kumar directly holds 652,000 shares of Anixa Biosciences common stock. This reflects an increase of 5,000 shares from the July 27, 2026 transaction at a reported price of $3.44 per share.

What was the price paid in the latest ANIX insider share purchase?

The latest insider purchase of ANIX shares was executed at $3.44 per share for 5,000 shares. The transaction, dated July 27, 2026, was categorized as a purchase in an open market or private transaction by CEO Amit Kumar.

Was the July 27, 2026 ANIX insider trade under a Rule 10b5-1 plan?

The Rule 10b5-1 checkbox for this ANIX Form 4 filing was not marked as affirmed, indicating the trade was not reported as pursuant to a Rule 10b5-1 trading plan. The transaction is identified simply as a purchase.

What type of security did ANIX’s CEO acquire in the recent Form 4?

ANIX’s CEO, Amit Kumar, acquired common stock in the recent Form 4 transaction. He purchased 5,000 shares on July 27, 2026 at $3.44 per share, increasing his directly held ownership to 652,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KUMAR AMIT

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CALIFORNIA 95118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		P		5,000	A	$3.44	652,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Amit Kumar	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)